Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IDH1-Associated m6A Methylation Is Linked to Transcriptomic Heterogeneity in Glioma.

CancersĀ·2026
Same author

Clinical utility of a blood based assay for the detection of IDH1.R132H-mutant gliomas.

Nature communicationsĀ·2024
Same author

Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma.

Clinical cancer research : an official journal of the American Association for Cancer ResearchĀ·2024
Same author

CDKN2A/B Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition.

Clinical cancer research : an official journal of the American Association for Cancer ResearchĀ·2024
Same author

IDH-mutant glioma: A new IDH1 inhibitor moves forward.

Neuro-oncologyĀ·2022
Same author

Body imaging for newly diagnosed CNS lymphoma: Evaluating the utility of the evaluation.

Neuro-oncologyĀ·2022

Related Experiment Video

Updated: Sep 25, 2025

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

584

Targeting IDH-Mutant Glioma.

Julie J Miller1

  • 1Department of Neurology, Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Julie.miller@mgh.harvard.edu.

Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|April 27, 2022
PubMed
Summary

Targeted therapies are being developed for isocitrate dehydrogenase (IDH)-mutant gliomas, offering new hope beyond non-curative standard treatments. These strategies exploit unique tumor biology to improve outcomes for patients with IDH-mutant brain tumors.

Keywords:
2-HydroxyglutarateAstrocytomaGliomaIDH1MetabolismOligodendroglioma

More Related Videos

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
09:43

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

8.2K
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

8.0K

Related Experiment Videos

Last Updated: Sep 25, 2025

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

584
Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
09:43

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

8.2K
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

8.0K

Area of Science:

  • Oncology
  • Neuro-oncology
  • Molecular Biology

Background:

  • Standard treatments for IDH-mutant gliomas (radiation, chemotherapy) are non-curative and cause neurotoxicity.
  • IDH-mutant gliomas possess unique biological characteristics driving research into targeted therapies.
  • There is a critical need for more effective and less toxic treatment options for these brain tumors.

Purpose of the Study:

  • To review emerging targeted therapeutic strategies for IDH-mutant gliomas.
  • To highlight advancements in understanding the specific biology of IDH-mutant tumors.
  • To discuss novel treatment approaches targeting IDH-mutant specific vulnerabilities.

Main Methods:

  • Literature review of preclinical and clinical studies on IDH-mutant glioma treatments.
  • Analysis of IDH-mutant specific targeting strategies currently in development.
  • Synthesis of information on direct IDH inhibitors and vulnerability-based approaches.

Main Results:

  • Significant progress has been made in identifying and developing IDH-mutant specific therapies.
  • Various targeted strategies, including direct IDH inhibitors, are in different phases of clinical development.
  • Approaches leveraging IDH-mutant specific vulnerabilities are also under investigation.

Conclusions:

  • Targeted therapies hold promise for improving outcomes in IDH-mutant gliomas.
  • Further research and clinical trials are essential to validate these novel treatment strategies.
  • Exploiting IDH-mutant biology offers a promising avenue for developing curative treatments.